Home TRAD Events Doctors Decide Project Sign me up
Overview Global Vision VTE and Cancer News The Team Projects Publications Partners & Funders Patient Stories
Home

Join our Newsletter

Name

Email (required)

TRAD Alliance Membership

Mail: TRADAlliance@cardiff.ac.uk

2014

Lim WY, Bozas G, Noble S, Hart S, Maraveyas A. Anticoagulating the subsegmental pulmonary embolism in cancer patients: a survey amongst different medical specialties. Journal of Thrombosis and Thrombolysis. 2014 Oct 18. [Epub ahead of print]   


Ettelaie C, Collier ME, Maraveyas A, Ettelaie R. Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures. Journal of Extracell Vesicles. 2014 Aug 13;3. doi: 10.3402/jev.v3.23592. eCollection 2014.


Echrish HH, Xiao Y, Madden LA, Allgar V, Cooke J, Wedgwood K, Dasgupta D, Greenman J, Maraveyas A. Effect of resection of localized pancreaticobiliary adenocarcinoma on angiogenic markers and tissue factor related pro-thrombotic and pro-angiogenic activity. Thrombosis Research. 2014 Aug;134(2):479-87.


Smith JD, Baillie J, Baglin T, Griffiths GO, Casbard A, Cohen D, Fitzmaurice DA, Hood K, Rose P, Cohen AT, Johnson M,Maraveyas A, Bell J, Toone H, Nelson A, Noble SI.  A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study. Trials. 2014 Apr 12;15:122.


Collier ME, Maraveyas A, Ettelaie C. Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles. Journal of Thrombosis and Haemostasis. 2014 Apr 1;111(4):647-55


2013

Chiu K, Razack A, Maraveyas A. Isolated pancreatic heamorrhage in association with anticoagulation. Thrombosis Journal. 2013 Oct 1;11(1):20.


Collier ME, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Journal of Thrombosis and Haemostasis. 2013 Nov;110(5):966-76.


Palmer J, Bozas G, Stephens A, Johnson M, Avery G, O'Toole L, Maraveyas A. Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients. BMC Health Services Research. 2013 Jun 27;13:235.


Date K, Hall J, Greenman J, Maraveyas A, Madden LA. Tumour and microparticle tissue factor expression and cancer thrombosis.Thrombosis Research. 2013 Feb;131(2):109-15.


Ettelaie C, Elkeeb AM, Maraveyas A, Collier ME. p38α phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles. Biochimica et Biophysica Acta (BBA). 2013 Mar;1833(3):613-21.


Ettelaie C, Collier ME, Mei MP, Xiao YP, Maraveyas A. Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro. Journal of Thrombosis and Haemostasis. 2013;109(1):61-71


Date K, Hall J, Greenman J, Maraveyas A, Madden LA. Tumour and microparticle tissue factor expression and cancer thrombosis. Throb Res. 2013 feb;131(2):109-15. doi:10.1016/j.thromres.2012.11.013. Epub 2012 Dec 11.


2012

Ettelaie C, Elkeeb AM, Maraveyas A, Collier ME.p39a phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles. Biochim Biophys Acta. 2012 Nov 26;1833(3);613-621.


Sheard L, Noble S, Prout H, Maraveyas A, Watt I, Dowding D, Johnson MJ. Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients - A qualitative study. Pall Med 2012 Published online before print October 23, 2012, doi: 10.1177/0269216312461678


Bozas G, Ramasamy S, Avery G, Maraveyas A. Unsuspected visceral venous thrombosis, in patients with cancer of the gastrointestinal system. Thromb Res. 2012 Oct;130(4):682-4


Welsh J, Smith JD, Yates KR, Greenman J, Maraveyas A, Madden LA. Tissue factor expression determines tumour cell coagulation kinetics. Int J Lab Hematol. 2012 Aug;34(4):396-402. doi: 10.1111/j.1751-553X.2012.01409.x. Epub 2012 Feb 20.


Yates KR, Welsh J, Udegbunam NO, Greenman J, Maraveyas A, Madden LA. Duramycin exhibits antiproliferative properties and induces apoptosis in tumour cells. Blood Coagul Fibrinolysis. 2012 Jul;23(5):396-401.


Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012 Jun;48(9);1283-92.


Johnson MJ, Sheard L, Noble S, Maraveyas A, Prout H, Watt I, Dowding D. Testing for and treating cancer associated thrombosis: choice of anticoagulant. Accepted for Poster Discussion Session. 6th International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, Italy, April 20-22, 2012


Sheard L, Prout H, Dowding D, Noble S, Watt I, Maraveyas A, Johnson MJ. The ethical decisions UK doctors make regarding advanced cancer patients at the end of life: the perceived (in) appropriateness of anticoagulation for venous thromboembolism. BMC Medical Ethics Sept 4, 2012, 13:22 doi: 10.1186/1472-6939-13-22


Johnson MJ, Sheard L, Maraveyas A, Noble S, Prout H, Watt I, Dowding D. Diagnosis and management of people with venous thromboembolism and advanced cancer: How do doctors decide? A qualitative study. BMC Medical Informatics and decision Making, 2012, Jul, 20;12:75 doi: 10.1186/1472-6947-12-75


Johnson MJ, Sheard L, Prout H, Noble S, Maraveyas A, Watt I, Dowding D. Testing for and treating venous thromboembolism: logistical and organisational issues. 7th World Research Congress of the European Association for Palliative Care (EAPC), Trondheim, Norway June 2012


Johnson MJ, Sheard L, Noble S, Prout H, Maraveyas A, Watt I, Dowding D. To be or not to be? Primary thromboprophylaxis in people with advanced cancer: view of oncologists and palliative physicians. 7th World Research Congress of the European Association for Palliative Care (EAPC), Trondheim, Norway June 2012


Maraveyas A, Palmer J, Avery G, Stephens S, Dean M, Elliot J, Hunter, Bozas G. Outcomes and characteristics of cancer patients with unsuspected PE managed under a specialist care pathway protocol - updated results. 6th International Conference on thrombosis and Hemostasis Issues in Cancer, Bergamo, Italy, April 20-22, 2012


Palmer J, Bozas G, Avery G, Stephens S, Maraveyas A. A pulmonary severity index (PESI)-based competency that underpins a modular outpatient nurse lead pulmonary embolism service for cancer patients. 6th International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, Italy, April 20-22, 2012


Johnson MJ, Sheard L, Noble S, Maraveyas A, Prout H, Watt I, Dowding D. Testing for and treating cancer associated thrombosis: choice of anticoagulant. Accepted for Poster Discussion session. 6th International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, Italy, April 20-22, 2012


Sheard L, Dowding D, Noble S, Maraveyas A, Prout H, Watt I, Johnson MJ. How do doctors decide whether it is appropriate or not to investigate and treat people with VTE and advanced cancer? The 9th Palliative Care Congress, Gateshead, UK March 2012


2011

Gillon S, Noble S, Ward J, Lodge K, Nunn A, Koon S, Johnson M. Primary Thrombo-prophylaxis for hospice in-patients? Who needs it? Palliative Medicine, 2011 http://www.ncbi.nlm.nih.gov/pubmed/21310773


Ettelaie C, Fountain D, Collier ME, Elkeeb AM, Xiao YP, Maraveyas. A Low molecular weight heparin down regulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-kB. Biochim Biophys Acta. 2011 Dec;1812(12):1591-600


Yates KR, Welsh J, Echrish HH, Greenman J, Maraveyas A, Madden LA. Pancreatic cancer cells and microparticle procoagulant surface characterization: involvement of membrane-expressed tissue factor, phosphatidylserine and phosphatidylethanolamine. Blood Coagul Fibrinolysis. 2011 Dec;22(8):680-7


Ettelaie C, Fountain D, Collier ME, Beeby E, Xiao YP, Maraveyas A. Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro. Exp. Ther. Med. 2011,2(2) 363-367


Echrish H, Madden LA, Greenman J, Maraveyas A. The hemostasis apparatus in pancreatic cancer and its importance beyond thrombosis cancers 2011, 3, 267-284


Bozas G, Palmer J, Avery G, Maraveyas A. Outcome and characteristics of cancer patients with incidental PE managed under a specialised care pathway protocol. 57th Congress of The International Society on Thrombosis and Hemostasis Kyotro Japan July 23-28 2011


2010

Maraveyas A, Johnson M, Xiao YP, Noble S.  Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins. Cancer and Metastasis Reviews 2010  Dec;29(4):777-84.


Noble SIR, Pasi J. Pathophysiology of cancer associated thrombosis. British Journal of Cancer. 2010;102;S2-S9


2009

Griffiths GO, Burns S, Noble SI, Macbeth FR, Maughan TS. FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC Cancer 2009 BMC Cancer 2009, 9:355.


Noble SIR, Jenkins DA. The management of venous thromboembolism in patients with cancer. British Journal of Hospital Medicine. 2009 8;70(7):380-385.


Johnson MJ. Noble SIR, Maraveyas A. Antithrombotic therapy in palliative care. Advances in Palliative Medicine. 2009; 8(3): 95-100


Maraveyas A and Johnson MJ. Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? British Journal of Cancer 2009; 100: 1837-1841; doi: 10.1038/sj.bjc.6605091


Noble S. A step in the right direction but one size might not fit all. Lancet Oncology 2009 Oct;10(10):930-1


Johnson MJ. Venous thromboembolism: not as easy as it looks. (Editorial) British Journal of Hospital Medicine. 2009; 70 (7): 176 – 177


Anthony Maraveyas. Pancreatic cancer: A model cancer for the study of the therapeutic effects of anticoagulants World J Gastrointest Oncol 2009 October 15; 1(1): 38-40


2008

Noble SI, Shelley M, Coles B, Williams S, Wilcock A, Johnson M. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis by the thrombosis task group, on behalf of the Association for Palliative Medicine Science Committee. Lancet Oncology 2008, 9(6):577-84


Sgouros J, Maraveyas A. Premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer.  Acta Oncol. 2008;47(3):337-46


Noble SIR, Nelson A, Finlay IG. Factors influencing hospice thromboprophylaxis policy: a qualitative study. Palliative Medicine, 4. 2008;22(7):808-13


Noble S. Venous thromboembolism in cancer patients. MIMS Oncology and Palliative Care. 2008; 2 (2):30-33


2007

Noble S. The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgraduate Medical Journal, 2007; 83: 671-674


Noble SIR, Hood K, Finlay IG. The use of long-term low molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliative Medicine, 2007; 21(6):473-6


Noble S. The management of venous thromboembolism in the palliative care setting. International Journal of Palliative Nursing. 2007, (13) 12, 574- 579


2006

Noble SIR, Finlay IG. Have Palliative Care Teams’ attitudes to venous thromboembolism changed? A survey of thromboprophylaxis practice across British Specialist Palliative Care Units in the years 2000 and 2005 Journal of Pain and Symptom Management. 2006 Jul;32(1):38-43.


Noble S, Nelson A, Turner C, Finlay I. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ 2006 Mar 11;332(7541):577-80.


Noble S, Nelson A. Palliative care can include prophylaxis. NT. Apr 2006. 102 (14) 16


2005

Noble SIR, Finlay IG.  Is long-term low molecular weight heparin  acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliative Medicine. 2005; 19: 197-201


Noble SIR. Home-treatment of deep vein thrombosis in patients with cancer: quality of life impact of therapies. Haematologica.  2005 Nov;90 Suppl:ELT06.


Noble SIR. Anticoagulation in advanced malignancy. Thrombus 2005; 8(4): 1-3


2001

Johnson MJ. Anticoagulation and patients with advanced cancer. CME Bulletin Palliative Care. 2001;


1999

Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clinical Oncology. 1999; 11: 105–110.


Johnson MJ, Walker ID, Sproule MW, Conkie J. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clinical and Laboratory Haematology. 1999: 21; 51–54.


Johnson MJ. Venous thromboembolism and advanced cancer. Palliative Care Today. 1999; 8: 6–7.


1997

Johnson MJ. Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliative Medicine. 1997; 11: 306–312.(correction Palliative Medicine. 1998; 12: 463.)


Johnson MJ, Sherry K. How do palliative physicians manage venous thromboembolism? Palliative Medicine. 1997; 11: 462–468.